Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Michael A. Grosso"'
Autor:
Rushad Patell, Charles Hsu, Minggao Shi, Michael A. Grosso, Anil Duggal, Harry R. Buller, Gary Raskob, Jeffrey I. Zwicker
Publikováno v:
Haematologica, Vol 109, Iss 6 (2023)
Thrombocytopenia occurs frequently in patients with cancer-associated thrombosis (CAT), however prospective evaluation of clinical outcomes following randomization to anticoagulants is limited. The HOKUSAI VTE Cancer study was a randomized, open-labe
Externí odkaz:
https://doaj.org/article/13859d1fc1a340ee999c569237cc3101
Autor:
Ingrid M. Bistervels, Roisin Bavalia, Jan Beyer‐Westendorf, Arina J. tenCate‐Hoek, Sebastian M. Schellong, Michael J. Kovacs, Nicolas Falvo, Karina Meijer, Dominique Stephan, Wim G. Boersma, Marije tenWolde, Francis Couturaud, Peter Verhamme, Dominique Brisot, Susan R. Kahn, Waleed Ghanima, Karine Montaclair, Amanda Hugman, Patrick Carroll, Gilles Pernod, Olivier Sanchez, Emile Ferrari, Pierre‐Marie Roy, Marie‐Antoinette Sevestre‐Pietri, Simone Birocchi, Hilde S. Wik, Barbara A. Hutten, Michiel Coppens, Christiane Naue, Michael A. Grosso, Minggao Shi, Yong Lin, Isabelle Quéré, Saskia Middeldorp, the Hokusai PTS Investigators
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 5, Pp n/a-n/a (2022)
Abstract Background Postthrombotic syndrome (PTS) is a long‐term complication after deep vein thrombosis (DVT) and can affect quality of life (QoL). Pathogenesis is not fully understood but inadequate anticoagulant therapy with vitamin K antagonist
Externí odkaz:
https://doaj.org/article/0df21bbe9243416c846a58adaeb27c35
Autor:
Cornelia Heleen vanOmmen, Manuela Albisetti, Anthony K. Chan, Jeremie Estepp, Julie Jaffray, Gili Kenet, Guy Young, Jay Dave, Michael A. Grosso, Anil Duggal
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 5, Pp 886-892 (2020)
Abstract Background Little evidence is available for treatment of pediatric venous thromboembolism (VTE). Large randomized controlled trials are challenging in children. Current antithrombotic agents have many limitations, including nonoral administr
Externí odkaz:
https://doaj.org/article/a753ebf843a74871b0ac1d681fd12efa
Autor:
Roisin Bavalia, Ingrid M. Bistervels, Wim G. Boersma, Isabelle Quere, Dominique Brisot, Nicolas Falvo, Dominique Stephan, Francis Couturaud, Sebastian Schellong, Jan Beyer‐Westendorf, Karine Montaclair, Waleed Ghanima, Marije ten Wolde, Michiel Coppens, Emile Ferrari, Olivier Sanchez, Patrick Carroll, Pierre‐Marie Roy, Susan R. Kahn, Karina Meijer, Simone Birocchi, Michael J. Kovacs, Amanda Hugman, Hugo ten Cate, Hilde Wik, Gilles Pernod, Marie‐Antoinette Sevestre‐Pietri, Michael A. Grosso, Minggao Shi, Yong Lin, Barbara A. Hutten, Peter Verhamme, Saskia Middeldorp, the Hokusai post‐PE study investigators
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 5, Pp n/a-n/a (2021)
Abstract Background Long‐term sequelae of acute pulmonary embolism (PE) include decreased quality of life (QoL). Evidence suggests that adequacy of initial anticoagulant treatment in the acute phase of venous thrombosis has a key impact on late pos
Externí odkaz:
https://doaj.org/article/9d304d4f7ddc45cebfc27bba1df82c7c
Autor:
Marjolein P. A. Brekelmans, Harry R. Büller, Michele F. Mercuri, Walter Ageno, Cathy Z. Chen, Alexander T. Cohen, Nick van Es, Michael A. Grosso, Andria P. Medina, Gary Raskob, Annelise Segers, Thomas Vanassche, Peter Verhamme, Philip S. Wells, George Zhang, Jeffrey I. Weitz
Publikováno v:
TH Open, Vol 02, Iss 01, Pp e1-e7 (2018)
Pulmonary embolism (PE) studies used direct oral anticoagulants (DOACs) with or without initial heparin. We aimed to (1) evaluate if PE patients benefit from initial heparin; (2) describe patient characteristics in the DOAC studies; and (3) investiga
Externí odkaz:
https://doaj.org/article/834b7b370e214a23b27ecd10f0a037ed
Autor:
Michael A. Portman, Jeffrey P. Jacobs, Jane W. Newburger, Felix Berger, Michael A. Grosso, Anil Duggal, Ben Tao, Neil A. Goldenberg, Matthew Brothers, Bradley Marino, Charles Canter, Mark Law, Nguyenvu Nguyen, Charlie Sang, Kristin Shimano, Dipankar Gupta, Michael Portman, Derek Williams, Lauren Glass, Charles Sperrazza, Steven Herold, Ruchira Garg, Mark Vranicar, Sawsan Awad, Alfred Asante-Korang, Colleen Druzgal, Caroline Ozment, Kamill Del Toro, Ferran Roses, Christian Jux, Verena Gravenhorst, Ulrich Schweigmann, Mihir Bhatt, Christine Sabapathy, Nagib Dahdah, Dototea Bartonicek, Gerald Tulzer, Elena Basargina, Tatiana Zvereva, Tatiana Pertels, Irina Plotnikova, S.E.G.U.E.L.A. Pierre-Emmanuel, Pascal Amedro, Dulac Yves, Damien BONNET, Paola Saraco, Alessandro Rimini, Valerii Digtiar, Margaryta Gonchar, Tetyana Kryuchko, Olga Yablon, Varinder Singh Bedi, Jashvant Patel, Monjori Mitra, Jacek Kusa, Kowalczyk Domagala, László KÖRNYEI, Csaba BERECZKI, László ABLONCZY, Vivianne Aviva Levitas, David Mishali, Shoshana Revel-Vilk, Dan Harlev, Hatice Ilgen Sasmaz, Namik Yasar Ozbek, Sule Unal, Türkan Patıroglu, Baris Malbora, Hasan Agin, Zeynep Karakas, Ramazan Kaan Kavakli, Elizabeth Chalmers, Frances Bu'Lock, Piers Daubeney, Hala Hamza, Mohamed Badr, Mohsen Elalfy, Ahmed Mansour, Hoda Hassab, Ayman Sabry, Linda Daou, Fadi Bitar
Publikováno v:
Journal of the American College of Cardiology. 80:2301-2310
Standard of care (SOC) anticoagulation for thromboembolism (TE) prevention in children with cardiac disease includes low molecular weight heparins or vitamin K antagonists. Limited data exists for alternate use of direct oral anticoagulants in childr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bc9820f0798cc8f0ac3ae00a75a96f1
https://doi.org/10.1016/j.jacc.2022.09.031
https://doi.org/10.1016/j.jacc.2022.09.031
Autor:
Thomas Vanassche, Rachel P. Rosovsky, Fares Moustafa, Harry R. Bu¨ller, Annelise Segers, Indu Patel, Minggao Shi, Naoki Miyoshi, Venkatesh Mani, Zahi Fayad, Dominique Stephan, Jeannot Schmidt, Michael A. Grosso, Victor F. Tapson, Peter Verhamme, Menno V. Huisman
Publikováno v:
Journal of Thrombosis and Haemostasis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfad99ffa9ef49704939a8277178fc68
https://doi.org/10.1016/j.jtha.2023.04.037
https://doi.org/10.1016/j.jtha.2023.04.037
Autor:
Ophelia, Yin, Tarundeep, Kakkar, Anil, Duggal, Masakatsu, Kotsuma, Minggao, Shi, Hans, Lanz, Michael A, Grosso
Publikováno v:
Clinical Pharmacology in Drug Development. 11:666-674
Edoxaban 60 mg is approved for stroke prevention in patients with atrial fibrillation (AF) not fulfilling any dose-reduction criteria. As edoxaban is partially renally cleared (≈50%), this study compared pharmacokinetics (PK) and pharmacodynamics o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fee09c0d25ac9d66cc8a83ac8d141d2
https://doi.org/10.1002/cpdd.1050
https://doi.org/10.1002/cpdd.1050
Autor:
Rushad Patell, Minggao Shi, Michael A. Grosso, Anil Duggal, Harry Büller, Gary E. Raskob, Jeffrey I. Zwicker
Publikováno v:
Blood. 140:5675-5676
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f8a8788a850a04cd6d88ced73b9d679
https://doi.org/10.1182/blood-2022-163507
https://doi.org/10.1182/blood-2022-163507
Autor:
Hans Lanz, Michael A. Grosso, Eugene Braunwald, Jeong-Gun Park, João Morais, Assen Goudev, Miodrag Ostojic, Elliott M. Antman, Christian T. Ruff, Anna Plitt, Robert P. Giugliano
Publikováno v:
International Journal of Cardiology. 304:185-191
Background Diabetes mellitus is an independent risk factor for stroke and atrial fibrillation. Therefore, the risk/benefit profile of the oral factor Xa inhibitor edoxaban stratified by diabetes is of clinical interest. Methods 21,105 patients enroll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::089a833e6310e10b65a2bf215ac4ff16
https://doi.org/10.1016/j.ijcard.2020.01.009
https://doi.org/10.1016/j.ijcard.2020.01.009